Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAIS Frühblüher
- Development stage
- Phase 2
- Lead developer
- Lofarma
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual
01
Overview
Lais Frühblüher sublingual drops is a sublingual allergen immunotherapy (SLIT) product developed by Lofarma S.p.A. for the treatment of birch and tree pollen-induced allergic rhinoconjunctivitis. The active ingredient is a carbamylated monomeric tree pollen allergoid, a biological extract chemically modified through carbamylation with potassium cyanate at alkaline pH. This modification significantly reduces the allergen's IgE-binding capacity, thereby lowering the risk of systemic allergic reactions, while preserving its immunogenicity to induce T-cell-mediated immune tolerance. The drug is formulated as sublingual drops and has been evaluated in Phase 2 clinical trials in Germany to assess its safety, tolerability, and clinical efficacy in patients with seasonal allergic rhinitis induced by early-blooming tree pollens.
- Brand names
- LAISLais FrühblüherLAIS Frühblüher sublingual drops
- Other names
- carbamylated monomeric tree pollen allergoidmonomeric allergoid tree pollencarbamylated monomeric tree pollen allergoid sublingual drops
02
Targets
Allergen-specific immunoglobulin E / B-cell receptor paratopes recognizing early-flowering pollen allergensIgE (Immunoglobulin E)
Beyond the preview
Go deeper on LAIS Frühblüher.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LAIS Frühblüher.